Medicenna Therapeutics Corp (NASDAQ:MDNA) Stock Gains Momentum: Now What?
Medicenna Therapeutics Corp (NASDAQ:MDNA) has appointed John H. Sampson, MD, PhD, MBA, to its Board of Directors. Fahar Merchant, PhD, President and CEO of Medicenna, is elated to welcome a world renowned clinician-scientist into their fold. He believes his expertise in leading novel clinical trials, interactions with regulators and translational immuno-oncology, will pave the way to develop MDNA11, enhance their MDNA55 program with a partnership, and build on their Superkine…